Abstract
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Volume: 7 Issue: 3
Author(s): Wim J. Oyen, E. J. Postema, Frans H. Corstens, Otto C. Boerman and Manuel J. Koppe
Affiliation:
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Abstract: Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Export Options
About this article
Cite this article as:
Oyen J. Wim, Postema J. E., Corstens H. Frans, Boerman C. Otto and Koppe J. Manuel, Radionuclide Therapy of Cancer with Radiolabeled Antibodies, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618126
DOI https://dx.doi.org/10.2174/187152007780618126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer
Current Cancer Therapy Reviews Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Stimuli-responsive Smart Liposomes in Cancer Targeting
Current Drug Targets Oxidised Products of Cholesterol: Their Role in Apoptosis
Current Nutrition & Food Science TNF as a Target of Inflammation in Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Transposons for Gene Therapy!
Current Gene Therapy Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design